HAVN Stock Overview
HAVN Life Sciences Inc., a biotechnology company, engages in the research and development of psychopharmacological products from plants and fungi.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
HAVN Life Sciences Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CA$0 |
| 52 Week High | CA$0.05 |
| 52 Week Low | CA$0.015 |
| Beta | -0.73 |
| 1 Month Change | n/a |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | n/a |
Recent News & Updates
Recent updates
Shareholder Returns
| HAVN | CA Biotechs | CA Market | |
|---|---|---|---|
| 7D | n/a | -6.4% | -2.1% |
| 1Y | n/a | -35.6% | 3.6% |
Return vs Industry: Insufficient data to determine how HAVN performed against the Canadian Biotechs industry.
Return vs Market: Insufficient data to determine how HAVN performed against the Canadian Market.
Price Volatility
| HAVN volatility | |
|---|---|
| HAVN Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 13.7% |
| Market Average Movement | 9.2% |
| 10% most volatile stocks in CA Market | 18.4% |
| 10% least volatile stocks in CA Market | 3.1% |
Stable Share Price: HAVN has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine HAVN's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2020 | n/a | Tim Moore | www.havnlife.com |
HAVN Life Sciences Inc., a biotechnology company, engages in the research and development of psychopharmacological products from plants and fungi. The Company also focuses on developing methodologies for the standardize and quality-controlled extraction of psychoactive compounds from plants and fungi, including Psilocybe spp. mushrooms; and the genera directive compounds, such as psilocybin, psilocin, and baeocystin, as well as the development of natural health care products from non-regulated compounds.
HAVN Life Sciences Inc. Fundamentals Summary
| HAVN fundamental statistics | |
|---|---|
| Market cap | CA$859.38k |
| Earnings (TTM) | -CA$15.71m |
| Revenue (TTM) | CA$586.98k |
0.0x
P/S Ratio0.0x
P/E RatioIs HAVN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| HAVN income statement (TTM) | |
|---|---|
| Revenue | CA$586.98k |
| Cost of Revenue | CA$378.37k |
| Gross Profit | CA$208.61k |
| Other Expenses | CA$15.92m |
| Earnings | -CA$15.71m |
Last Reported Earnings
Jan 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.55 |
| Gross Margin | 35.54% |
| Net Profit Margin | -2,676.59% |
| Debt/Equity Ratio | 3.1% |
How did HAVN perform over the long term?
See historical performance and comparison